ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor
ウェブ2008年5月1日 · In human tumor cells, ABT-263 induces Bax translocation, cytochrome c release, and subsequent apoptosis. Oral administration of ABT-263 alone induces complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia.
Navitoclax - Wikipedia
ウェブNavitoclax (previously ABT-263) is an experimental orally active anti- cancer drug, which is a Bcl-2 inhibitor similar in action to obatoclax. [1] [2] Mechanism of action. Navitoclax inhibits not only Bcl-2, but also Bcl-X L and Bcl-w proteins. [3] .
5月21日 慢性腎臓病（CKD）と細胞老化（5月19日号 Science ...
ウェブ2021年5月21日 · ABT-263処理により、老化マーカーを発現する細胞が減少させるとともに、急性腎障害による繊維化をおさえ、さらに尿細管細胞の再生増殖が高まる。すなわち、老化細胞の存在が、繊維化を高め再生を抑えていることを示し、senolysis治療
Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven ...
ウェブ2021年7月13日 · Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy | Cell Death & Disease. Article. Open access. Published: 13 July 2021. Bcl-2/Bcl-xL inhibitor...
Navitoclax (ABT-263) | ≥99%(HPLC) | Selleck | Bcl-2 阻害剤
ウェブナビトクラックス (Navitoclax (ABT-263)) は Bcl-xL, Bcl-2 and Bcl-w の強力な阻害剤であり、阻害定数は cell-free assay において Ki ≦ 0.5 nM, 1 nM および 1nM です。 一方、Mcl-1 および A1 に対しては比較的弱い結合力を示します。 臨床第2相試験中. CAS No. 923564-51-6. 文献中Selleckの製品使用例 （345） Gastroenterology,2024S0016-5085 …
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
ウェブ2008年5月1日 · ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor | Cancer Research | American Association for Cancer Research. Experimental Therapeutics, Molecular Targets, and Chemical Biology | May 01 2008. ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor. Christin Tse; Alexander R. Shoemaker; Jessica …
Targeting anti-apoptotic pathways eliminates senescent ...
ウェブ2022年12月23日 · We find that senescent melanocytes translationally upregulate MCL-1 in response to ABT-263 as a mechanism to evade ABT-263-mediated apoptosis. This phenomenon is mainly regulated by mTOR, and the ...
ABT-263 induces G1/G0-phase arrest, apoptosis and ...
ウェブ2017年7月10日 · ABT-263 (Navitoclax), a novel BH3 mimetic and orally bioavailable Bcl-2 family inhibitor with high affinity for Bcl-xL, Bcl-2 and Bcl-w has entered clinical trials for cancer treatment. But the...
ABT-263 Reduces Hypertrophic Scars by Targeting Apoptosis ...
ウェブ2021年1月14日 · ABT-263, as an orally bioavailable BCL-2 family inhibitor, has showed great antitumor characteristics by targeting tumor cell apoptosis. The objective of this study was to explore whether ABT-263 could target apoptosis of overactivated myofibroblasts in hypertrophic scar. Methods: In vivo, we used ABT-263 to treat scars …
Discovery of ABT-263, a Bcl-family protein inhibitor ...
ウェブBackground: The discovery of ABT-263, a rationally designed Bcl-2/Bcl-xL inhibitor at present in Phase I clinical trials for cancer, is described. Emphasis is placed on the specific hurdles overcome throughout the discovery process that relate to the nature of the targeted protein-protein interaction (PPI).
コンテンツに移動